Seasonal influenzain primary care settings: Review for primary care physicians

Wisconsin Medical Journal

Volumn 109, Issue 4, 2010, Pages 193-200

  Temte, Jonathan L ^a   Prunuske, Jacob P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

AMBULATORY CARE; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COUGHING; DELIRIUM; DIAGNOSTIC TEST; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; FEVER; HALLUCINATION; HEADACHE; HEALTH SURVEY; HUMAN; INFLUENZA; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INSOMNIA; NAUSEA; NERVOUSNESS; PANDEMIC; PATHOGENESIS; PRIMARY MEDICAL CARE; PROFESSIONAL PRACTICE; PUBLIC HEALTH; RESPIRATORY TRACT INFECTION; SEASONAL INFLUENZA; SEIZURE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; DISEASE TRANSMISSION; EPIDEMIC; PRIMARY HEALTH CARE; REVIEW; SEASON;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; PRIMARY HEALTH CARE; SEASONS;

EID: 77957004052     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Temte JL. Basic rules of influenza: how to combat the H1N1 influenza (swine flu) virus. Am Fam Physician. 2009;79(11):938-939.
2. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26 Suppl 4:D49-53.
3. Kilbourne ED. Influenza. New York, NY: Plenum Medical Book Company;1987:359.
4. Chen J, Deng YM. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J. 2009;6:30.
5. Beigel JH, Farrar J, Han AM, et al. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-1385.
6. Glezen WP, Couch RB. Influenza viruses. In: Evans AS, Kaslow RA, eds. Viral Infections of Humans. Epidemiology and Control. 4th ed. New York, NY: Plenum Medical Book Company;1987:473-505.
7. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:775-785.
8. Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500.
9. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007;3:1470-1476.
10. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2009;58(RR-8):1-52.
11. Ghedin E, Wentworth D, Halpin RA, et al. Unseasonal transmission of H3N2 influenza A virus during the swine-origin H1N1 pandemic. J Virol. 2010 Mar 17. [Epub ahead of print] PMID: 20237080.
12. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12:9-14.
13. World Health Organization. Pandemic (H1N1) 2009 - update 93. Weekly update. http://www.who.int/csr/don/2010_03_26/en/index.html. Accessed July 29, 2010.
14. Lessler J, Reich NG, Brookmeyer R, et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291-300.
15. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998;101:643-649.
16. Dolin R. Influenza: current concepts. Am Fam Physician. 1976;14:72-77.
17. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243-3247.
18. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis. 2006;43:564-568.
19. Little JW, Hall WJ, Douglas RG Jr, et al. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis. 1978;118:295-303.
20. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096.
21. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? a systematic review. BMC Infect Dis. 2006;6:130.
22. Yassi A, Mcgill M, Holton C, Nicolle L. Morbidity, cost and role of health care worker transmission in an outbreak in a tertiary care hospital. Can J Infect Dis. 1993;4:42-56.
23. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA. 2009;302:1865-1871.
24. Larson EL, Lin SX, Gomez-Pichardo C, Della-Latta P. Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms. Ann Intern Med. 2004;140:321-329.
25. CDC. ACIP provisional recommendations for the use of influenza vaccines. http://www.cdc.gov/vaccines/recs/provisional/default.htm#acip. Accessed July 29, 2010.
26. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions. The PRISMA Study. Arch Intern Med. 2005;165:274-280.
27. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165-1174.
28. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ. 2006;333:1241.
29. Skowronski DM, Tweed SA De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008;197:490-502.
30. Demicheli V, Di Pietrantonj C, Jefferson, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub3.
31. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555-1564.
32. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355:2513-2522.
33. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303:943-950.
34. Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD004879. DOI: 10.1002/14651858.CD004879.pub3.
35. Fleming DM, Crovari P, Wahn U, et al; the CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869.
36. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR 2008;57(RR-7):1-60.
37. Nelson MI, Simonsen L, Viboud C, et al. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology. 2009;388:270-278.
38. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303-313.
39. FDA MedWatch 2006 Jan 4:www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152874.htm. Accessed July 29, 2010.
40. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract. 2009;63:596-605.
41. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med. 2007;9:23.
42. Dharan NJ, Gubareva LV, Meyer JJ, et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034-1041.
43. Temte JL. Heterogeneity in estimating H1N1. BMJ [rapid response]. Posted on 8/16/2009 at:http://www.bmj.com/cgi/eletters/339/jul14_3/b2840. Accessed July 29, 2010.
44. Zambon M, Hays J, Webster A, et al. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161:2116-2122.
45. Hurt AC, Alexander R, Hibbert J, et al. Performance of 6 influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol. 2007;39:132-135.
46. Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 2009. MMWR 2009;58:826-829.
47. Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract. 2000;50:817-820.
48. Matheson NJ, Harnden AR, Perera R, et al.Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2007;(1):CD002744.
49. Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig. 2006;26:329-340.
50. Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol. 2007;165:212-221.
51. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.
52. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomized controlled trials. BMJ. 2009339:b3172.
53. Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:537-545.
54. Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123-129.
55. Temte JL. Telephone triage of patients with influenza. Am Fam Physician. 2009;79:943-945.
56. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568-1575.
57. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48:1254-1256.
58. Buffington J, Chapman LE, Schmeltz LM, Kendal AP. Do family physicians make good sentinels for influenza? Arch Fam Med. 1993;2:858-865.